Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis - Possible role in vascular inflammation

Rheumatology

Volumn 46, Issue 9, 2007, Pages 1422-1427

  Bjerkeli, Vigdis ^a   Damås, Jan Kristian ^a   Fevang, Børre ^a   Holter, Jan Cato ^a   Aukrust, Pål ^a   Frøland, Stig S ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Chemokines; Fractalkine; Inflammation; Mononuclear cells; Wegener's granulomatosis

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CX3CR1; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; FRACTALKINE; IMMUNOGLOBULIN; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; PREDNISOLONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL ADHESION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYPOTHESIS; MALE; MONOCYTE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; T LYMPHOCYTE; WEGENER GRANULOMATOSIS;

ADULT; AGED; AGED, 80 AND OVER; CD4-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINES, CX3C; CHEMOTAXIS, LEUKOCYTE; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; WEGENER GRANULOMATOSIS;

EID: 34548227458     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem168     Document Type: Article

References (34)

1. Fauci A, Wolff S. Wegener's granulomatosis. Medicine 1973;73:535-61.
2. Jennette JC, Falk RJ, Andrassy K. Nomenclature of systemic vasculitides: proposal of an International Consensus Conference. Arthritis Rheum 1994;37:187-92.
3. Yi ES, Colby TV. Wagener's granulomatosis. Semin Diagn Pathol 2001;18:34-46.
4. Schnabel A, Csemok E, Braun J, Gross WL. Activation of neutrophils, eosinophils, and lymphocytes in the lower respiratory tract in Wegenses granulomatosis. Am J Respir Crit Care Med 2000;161:399-405.
5. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-42.
6. Coulomb-L'Hermine A, Capron F, Zou W et al. Expression of the chemokine RANTES in pulmonary Wagener's granulomatosis. Hum Pathol 2001;32:320-6.
7. Mayet W, Schwarting A, Barreiros AP, Schlaak J, Neurath M. Anti-PR-3 antibodies induce endothelial IL-8 release. Eur J Clin Invest 1999;29:973-9.
8. Ralston DR, Marsh CB, Lowe MP, Wewers MD. Antineutrophil cytoplasmic antibodies induce monocyte IL-8 release. Role of surface proteinase-3, alpha1-antitrypsin, and Fcgamma receptors. J Clin Invest 1997;100:1416-24.
9. Thorheim EA, Yndestad A, Bjerkeli V, Halvorsen B, Aukrust P, Frøland SS. Increased expression of chemokines in patients with Wegener's granulomatosis - modulating effects of methylprednisolone in vitro Clin Exp Immunol 2005;140:376-83.
10. Taekema-Roelvink ME, Kooten C, Kooij SV, Heemskerk E, Daha MR. Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular call adhesion molecule-1. J Am Soc Nephrol 2001;12:932-40.
11. Zhou Y, Huang D, Farver C, Hoffman GS. Relative Importance of CCR5 and antineutrophil cytoplasmic antibodies in patients with Wegener's granulomatosis. J Rheumatol 2003;30:1541-7.
12. 3CR1, which mediates both leukocyte migration and adhesion. Cell 1997;91:521-30.
13. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology. From basic research to clinical disease. Arterioscler Thromb Vasc Blot 2004;24:34-40.
14. Fong AM, Robinson LA, Steeber DA et al. Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion and activation under physiologic flow. J Exp Med 1998;188:413-9.
15. Yajima N, Kasama T, Isozaki T et al. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: Potential Involvement in neuropsychiatric manifestations. Arthritis Rheum 2005;52:1670-5.
16. Ito Y, Kawachi H, Morioka Y et al. Fractalkine expression and the recruitment of CX3CR1+ calls in the prolonged mesangial proliferative glomerulonephritis. Kidney Int 2002;61:2044-57.
17. Sawai H, Park YW, Roberson J, Imai T, Goronsy JJ, Weyand CM. T cell costimulation by fractalkine- expressing synoviocytes in rheumatoid arthritis. Arthritis Rheum 2005;52:1392-401.
18. Blaschke S, Koziolek M, Scwarz A, Benohr P, Middel P. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rhematol 2003;30:1918-27.
19. Jennette JC, Falk R.J, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
20. Luqmani RA, Bacon PA, Moole RJ et al. Birmingham vasculitis activity score (BVAS) in systemic necrotizing vasculitis. QJM 1994;87:671-8.
21. Aukrust P, Aandahl EM, Skålhegg BS et al. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunoll 1999;162:1178-85.
22. Stylianou E, Aukrust P, Müller F, Nordøy I, Frøland SS. Complex effects of interferon-α on the cytokine network in HIV infection - possible contribution to immunosuppression. Cytokine 2001;14:56-62.
23. Damås JK, Boullier A, Wæhre T et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc Biol 2005;25:2567-72.
24. Yndestad A, Holm AM, Müller F et al. Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure. Cardiovasc Res 2003;60:141-6.
25. Cockwell P, Brooks CJ, Adu D, Savage CO. Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 1999;55:852-63.
26. Cockwell P, Howie AJ, Adu D, Savage CO. In situ analysis of C-C chemokine mRNA in human glomerulonephritis. Kidney Int 1998;54:827-38.
27. Inoue A, Hasegawa H, Kohno M et al. Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice. Arthritis Rheum 2005;52:1522-33.
28. Cockwell P, Chakravorty SJ, Girdlestone J, Savage CO. Fractalkine expression in human renal inflammation. J Pathol 2002;196:85-9.
29. Green SR, Han KH, Chen Y et al. The CC chemokine MCP-1 stimulates surface expression of CX3CR1 and enhances the adhesion of monocytes to fractalkine/CX3CL1 via p38 MAPK. J Immunol 2006;176:7412-20.
30. Lamprecht P, Kumanovics G, Mueller A et al. Elevated monocytic IL-12 and TNF-α production in Wegener's granulomatosis is normalized by cyclophosphamide and corticosteroid therapy. Clin Exp Immunol 2002;128:181-6.
31. Csernok E, Trabandt A, Müller A et al. Cytokine profiles in Wagener's granulomatosis: Predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999;42:742-50.
32. Nishimura M. Umehara H, Nakayama T et al. Dual function of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression. J Immunol 2002;168:6173-80.
33. Fraticelli P, Sironi M, Bianchi G et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. J Clin Invest 2001;107:1173-81.
34. Furuichi K, Wada T, Iwata Y et al. Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron 2001;87:314-20.